Moleculin Reports 60% of First 45 Subjects in Pivotal "MIRACLE" Phase 3 AML Trial Consented

Stock Information for Evolution Petroleum Corporation Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evolution Petroleum Corporation Inc.

Moleculin to Participate in the Virtual Investor Closing Bell Series
Moleculin Announces Reverse Stock Split
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.